您所在的位置: 首页 --> 导师团队 --> 李惠平

导师基本信息

  • 姓名:李惠平
  • 性别:
  • 民族:汉族
  • 科室:乳腺肿瘤内科
  • 职称:主任医师 ,教授
  • 专业:肿瘤学 、肿瘤内科学
  • E-MAIL: huipingli2012@hotmail.com

学术论文 | 科研项目 | 招生计划

李惠平* 邵彬 王晶 宋国红 邸立军 梁旭 严颖 王丽娜 刘笑然,依维莫司治疗激素受体阳性进展期乳腺癌疗效和安全性的回顾性研究 ,癌症进展 ,2015,13(2):120-124

Wangshu Zheng, Wenzhe Li, Ping Li, Ling Zhu, Xiaoran Liu, Bin Shao, Huiping Li*, Chen Wang*, Yanlian Yang*. Peptide-Functionalized Nanomaterials for the Efficient Isolation of HER2-Positive Circulating Tumor Cells ,ACS APPLIED MATERIALS & INTERFACES ,9(22):18423-18428

Mingxing Zhou, Hui Zheng, Zhaoba Wang, Ren Li, Xiaoran Liu, Weikai Zhang, Zihua Wang, Huiping Li*, Zewen Wei* and Zhiyuan Hu*. Precisely Enumerating Circulating Tumor Cells Utilizing a Multi-Functional Microfluidic Chip and Unique Image Interpretation Algorithm ,Theranostics ,7(19): 4710–4721

Liu XR, Shao B, Peng JX, Li HP, Yang YL, Kong WY, Song GH, Jiang HF, Liang X, Yan Y. Identification of high independent prognostic value of nanotechnology based circulating tumor cell enumeration in first-line chemotherapy for metastatic breast cancer patients. ,The Breast ,2017;32:119-125

Liu X, Li H, Shao B, Wu J, Kong W, Song G, Jiang H, Wang J, Wan F. Identification of recurrent BRCA1 mutation and its clinical relevance in Chinese Triple-negative breast cancer cohort. Cancer Med. ,Cancer Medicine ,2017;6(3):547-554

Huiping Li*, Bin Shao, Yin Yan, Guohong Song, Xiaoran Liu, Jing Wang, Xu Liang. Efficacy and safety of trastuzumab combined with chemotherapy for first-line treatment and beyond progression of HER2-overexpressing advanced breast cancer ,Chinese Journal of Cancer Research. ,28(3):330-338

Xiao-ran L, Bin S, Jia-xi P, Huip-ing L*, Yan-lian Y*, Wei-yao K, Guo-hong S, Han-Fang J, Xu L, Ying Y. Identification of high independent prognostic value of nanotechnology based circulating tumor cell enumeration in first-line chemotherapy for metastatic breast cancer patients. ,CANCER MEDICINE ,31; 32: 119-125

Xiao-ran L, Hui-ping L*, Bin S, Jian-min W, Wei-yao K, Guo-hong S, Han-fang J, Jing W, Feng-ling W. Identification of recurrent BRCA1 mutation and its clinical relevance in Chinese Triple-negative breast cancer cohort. ,Cancer Medicine ,6; 3: 547-554

PARP磷酸化水平与其在进展期乳腺癌治疗疗效的相关性研究 , 课题负责人 , 2016.7.25~2017.8.25, 江苏恒瑞制药有限公司

国内多中心激素受体阳性、HER-2阴性复发转移性乳腺癌一线治疗患者数据库的建立 , 课题负责人 , 2016.11.14~2018.1.14, 吴阶平医学基金会

难溶性药物口服纳米制剂的转运机制及临床转化研究 , 子课题负责人 , 2015.11.23~2019.8.23, 973

研究生招生计划
招生年度 招生专业 学位级别 学位类型 研究方向 选拔方式
2021 肿瘤内科学 长学制 专业学位 临床技能训练与研究 长学制二级学科培养
2021 肿瘤学 硕士 科学学位 乳腺肿瘤的临床和基础研究 全国统考